ReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory Authority
Groundbreaking Innovation Receives TGA Approval in Australia LEATHERHEAD, England, Dec. 2, 2024…
ReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory Authority
Groundbreaking Innovation Receives TGA Approval in Australia LEATHERHEAD, England, Dec. 2, 2024…
ReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory Authority
Groundbreaking Innovation Receives TGA Approval in Australia LEATHERHEAD, England, Dec. 2, 2024…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
SGS ACHIEVES RECOGNITION AS AN APPROVED LEAF MARQUE CERTIFICATION BODY
MUMBAI, India, Nov. 22, 2024 /PRNewswire/ -- SGS in India is proud…
Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
SGS ACHIEVES RECOGNITION AS AN APPROVED LEAF MARQUE CERTIFICATION BODY
MUMBAI, India, Nov. 22, 2024 /PRNewswire/ -- SGS in India is proud…
Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…